Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Core Insights - Protagonist Therapeutics, Inc. announced that clinical data on rusfertide in polycythemia vera will be presented at the 67th Annual American Society of Hematology (ASH) Annual Meeting [1] Presentation Details - The focus will be on the Phase 3 VERIFY study, which evaluates rusfertide compared to placebo plus current standard-of-care therapy for polycythemia vera [1] - The presenting author will be Dr. Andrew Kuykendall from Moffitt Cancer Center, with publication number 81 [1] - The oral session will be titled "Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study" [1]